Who
Natalie C. Holles
Director
Company insider
Files Form 4 as: Director, LeonaBio; Director and Officer, Aura Biosciences; Director, Day One Biopharmaceuticals; CEO, Third Harmonic Bio; Director, Rubius Therapeutics; Director, Allakos; President and COO, Audentes Therapeutics; SVP, Business Development, Hyperion Therapeutics.
In numbers
- Trades disclosed
- 112
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $412K
- Companies
- 8
- Companies where not an officer
- 4
- First trade
- 1 Jul 2013
- Last trade
- 23 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 24 Jun 2026 | LONA LeonaBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —2,333 at $0.00 | filing |
| 23 Jun 2026filed 24 Jun 2026 | LONA LeonaBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —2,333 at $0.00 | filing |
| 19 May 2026filed 19 May 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —600,118 at $0.00 | filing |
| 19 May 2026filed 19 May 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —553,844 at $0.00 | filing |
| 19 May 2026filed 19 May 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,169,103 at $0.00 | filing |
| 19 May 2026filed 19 May 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,169,103 at $0.00 | filing |
| 19 May 2026filed 19 May 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —600,118 at $0.00 | filing |
| 19 May 2026filed 19 May 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —553,844 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | LONA LeonaBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | LONA LeonaBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One BiopharmaceuticalsBiotechnology | SEC FORM 4 Code D | —57,310 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,300 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —40,300 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —28,700 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —37,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,335 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
News
No headline names them, or the companies they trade most, lately.